Glypromate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Glypromate
Accession Number
DB05633
Description

Neuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for the potential treatment of neurodegenerative diseases by IV infusion. In December 2008, the company discontinued further development of the drug after it failed to show an observable effect.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 301.299
Monoisotopic: 301.127385344
Chemical Formula
C12H19N3O6
Synonyms
  • Gly-pro-glu
  • Glycyl-prolyl-glutamic acid
  • GPE

Pharmacology

Indication

Investigated for use/treatment in neurologic disorders.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
ZYK4RVV5LS
CAS number
32302-76-4
InChI Key
JJGBXTYGTKWGAT-YUMQZZPRSA-N
InChI
InChI=1S/C12H19N3O6/c13-6-9(16)15-5-1-2-8(15)11(19)14-7(12(20)21)3-4-10(17)18/h7-8H,1-6,13H2,(H,14,19)(H,17,18)(H,20,21)/t7-,8-/m0/s1
IUPAC Name
(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}pentanedioic acid
SMILES
[H]N([H])CC(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCC(O)=O)C(O)=O

References

General References
Not Available
ChemSpider
2338502
ChEMBL
CHEMBL371315
ZINC
ZINC000003776571

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility14.7 mg/mLALOGPS
logP-3.2ALOGPS
logP-4.9ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)3.2ChemAxon
pKa (Strongest Basic)7.83ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area150.03 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity69.08 m3·mol-1ChemAxon
Polarizability28.23 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on November 18, 2007 11:26 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates